Titan Pharmaceuticals (TTNP) director reports 3,313-share, 6,250-option disposition
Rhea-AI Filing Summary
Titan Pharmaceuticals (TTNP) director Avraham Ben-Tzvi reported dispositions on 10/01/2025. The filing shows a sale/disposition of 3,313 shares of common stock and surrender/disposition of 6,250 options (two option groups of 1,250 and 5,000). After these transactions the reporting person reports 0 shares and 0 options beneficially owned in the issuer. The reported dispositions were made in connection with a merger and share-exchange under which Titan common shares and outstanding Titan options were exchanged for Black Titan securities per a Merger and Contribution and Share Exchange Agreement dated August 19, 2024.
Positive
- Transactions were executed under a disclosed Merger Agreement, providing a clear legal basis for the dispositions
- Reporting was timely and included signature, satisfying Section 16 filing formalities
Negative
- Reporting person shows 0 beneficial shares and options remaining, indicating no retained direct holdings in Titan following the exchange
- Filing does not disclose receipt details of Black Titan securities, leaving post-merger ownership unclear
Insights
Director disposed of all reported Titan holdings after a merger exchange.
The reporting person, a director, shows disposition of 3,313 common shares and surrender/exchange of 6,250 options on 10/01/2025, leaving 0 reported beneficial holdings in the issuer. The filing explicitly ties these transactions to the Merger and Contribution and Share Exchange Agreement dated 8/19/2024, under which Titan shares and options were exchanged for Black Titan securities.
The primary dependency is the merger exchange mechanics: common stock and options were treated as exchanged rather than market sales, which explains the option conversions and the reported zero holdings post-transaction. Monitor any subsequent Form 4 filings that disclose receipt of Black Titan securities or new holdings, as those would clarify ongoing beneficial ownership and potential lock-up periods.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Option to Purchase Common Stock | 1,250 | $0.00 | -- |
| Disposition | Option to Purchase Common Stock | 5,000 | $0.00 | -- |
| Disposition | Common Stock | 3,313 | $0.00 | -- |
Footnotes (1)
- Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger"). Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.
